In patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)

Deep molecular responses may have significant prognostic value1

Deep molecular response (≤0.1% IS BCR-ABL mRNA) at 18 months is associated with higher rates of1*:

EFS, Event-Free Survival
PFS, Progression-Free Survival

In a retrospective analysis comparing long-term outcomes between patients achieving and failing to achieve deep molecular response, those patients with MMR at 18 months had higher rates of EFS (95% vs 75%) and PFS (99% vs 90%).1

Prognostic value of deep response in CML treatment Prognostic value of deep response in CML treatment

International Scale (IS) RQ-PCR monitoring can detect early and deep molecular response1,2

  • MMR can be assessed on the International Scale1
  • IS RQ-PCR has the capability to monitor responses after patients have achieved CCyR3
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

*Compared with total no MMR population (>0.1% IS BCR-ABL mRNA).

Compared with patients whose BCR-ABL levels were >0.1% to ≤1.0% IS.

mRNA, messenger ribonucleic acid; MMR, major molecular response; RQ-PCR, real-time quantitative polymerase chain reaction; CCyR, complete cytogenetic response.

References: 1. Hughes TP, Hochhaus A, Branford S, et al. Blood. 2010;116(19):3758-3765. 2. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238. 3. Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed March 1, 2017. To view the most recent and complete version of the guideline, go online to